Technical Analysis for IMPL - Impel NeuroPharma, Inc.

Grade Last Price % Change Price Change
F 13.62 -2.37% -0.33
IMPL closed down 2.37 percent on Friday, May 14, 2021, on 55 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical IMPL trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
New 52 Week Closing Low Bearish -2.37%
Hot IPO Pullback Bullish Swing Setup -2.37%
New 52 Week Low Weakness -2.37%
Down 3 Days in a Row Weakness -2.37%
Older End-of-Day Signals for IMPL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 12 hours ago
Down 2 % about 12 hours ago
Down 1% about 12 hours ago
Fell Below Previous Day's Low about 12 hours ago
New 52 Week Low about 12 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Parkinson's Disease Migraine Central Nervous System Disease Treatment Of Migraine Prodrugs Autism Spectrum Disorder Carbidopa L Dopa Catecholamines Combination Drugs Late Stage Pharmaceutical

Is IMPL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.89
52 Week Low 13.55
Average Volume 118,821
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 14.67
Average True Range 0.49
ADX 0.0
+DI 4.66
-DI 29.71
Chandelier Exit (Long, 3 ATRs ) 14.42
Chandelier Exit (Short, 3 ATRs ) 15.02
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line -0.26
MACD Signal Line -0.10
MACD Histogram -0.1645
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.30
Resistance 3 (R3) 14.35 14.17 14.18
Resistance 2 (R2) 14.17 14.00 14.15 14.14
Resistance 1 (R1) 13.90 13.90 13.81 13.85 14.11
Pivot Point 13.72 13.72 13.68 13.70 13.72
Support 1 (S1) 13.45 13.55 13.36 13.40 13.13
Support 2 (S2) 13.27 13.45 13.25 13.10
Support 3 (S3) 13.00 13.27 13.06
Support 4 (S4) 12.95